Alagille Syndrome Trends Analysis, Growth Opportunites, Emerging Drugs, and Epidemiology Forecast (2030) | Key Companies – Mirum Pharmaceuticals, Albireo, and several Others

Alagille Syndrome Trends Analysis, Growth Opportunites, Emerging Drugs, and Epidemiology Forecast (2030) | Key Companies -  Mirum Pharmaceuticals, Albireo, and several Others
Delveinsight Business Research LLP
DelveInsight’s “Alagille Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Alagille Syndrome Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alagille Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Alagille Syndrome Market

Alagille Syndrome: An Overview

Alagille Syndrome (ALGS) is a multisystem autosomal dominant disorder with a wide variety of clinical manifestations. It is also known as arteriohepatic dysplasia, Alagille-Watson syndrome, Watson-Miller syndrome or syndromic bile duct paucity. The clinical manifestations are variable, even within the same family, and commonly include hepatic (cholestasis, characterized by bile duct paucity on liver biopsy), cardiac (primarily involving the pulmonary arteries), renal skeletal (butterfly vertebrae), ophthalmologic, and facial abnormalities.

Alagille Syndrome Market Key Facts

  • As per the National Institute of Health (NIH), the estimated prevalence of Alagille syndrome is 1 in 70,000 newborns. This figure is based on diagnoses of liver disease in infants and may be an underestimation because some people with Alagille syndrome do not develop the liver disease during infancy.

  • As per National Organization for Rare Disorders (NORD), Alagille syndrome affects males and females in equal numbers. The incidence of Alagille syndrome has been estimated to be approximately 1 in 30,000-45,000 individuals in the general population.

  • It has been observed that males and females are equally affected by Alagille Syndrome.

  • As per the Delveinsight, among the 7MM, the US accounts for approximately half of the Alagille Syndrome market share among the overall market size in 2017.

Get FREE sample copy @ Alagille Syndrome Therapeutics Market

Key Benefits of Alagille Syndrome Market Report

  • The report provides an in-depth analysis of Alagille Syndrome Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Alagille Syndrome Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Alagille Syndrome’s current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Alagille Syndrome market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Alagille Syndrome Market

Alagille Syndrome market size is expected to increase during the study period owing to the increasing incident/prevalent population of ALGS patients in the 7MM

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Alagille Syndrome market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Alagille Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Alagille Syndrome Epidemiology Forecast

The epidemiology section covers insights about the historical and current Alagille Syndrome patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Alagille Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alagille Syndrome market or expected to get launched in the market during the study period. The analysis covers Alagille Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Alagille Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

The available therapeutics treatment options in Alagille Syndrome Landscape aim to reduce complications arising due to genetic mutation. The dynamics of the Alagille Syndrome market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world.

Key companies in the Alagille Syndrome Market:

  • Mirum Pharmaceuticals 

  • Albireo

And many others.

Alagille Syndrome Therapies Covered in the report include:

  • Maralixibat (LUM001)

  • Odevixibat

And many more.

The pipeline for Alagille Syndrome (ALGS) portraits a high medical unmet need for a better treatment pattern in the market in upcoming years.

Request for Sample @ Alagille Syndrome Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Alagille Syndrome Competitive Intelligence Analysis

4. Alagille Syndrome Market Overview at a Glance

5. Alagille Syndrome Disease Background and Overview

6. Alagille Syndrome Patient Journey

7. Alagille Syndrome Epidemiology and Patient Population

8. Alagille Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Alagille Syndrome Unmet Needs

10. Key Endpoints of Alagille Syndrome Treatment

11. Alagille Syndrome Marketed Products

12. Alagille Syndrome Emerging Therapies

13. Alagille Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Alagille Syndrome Market Outlook (7 major markets)

16. Alagille Syndrome Access and Reimbursement Overview

17. KOL Views on the Alagille Syndrome Market.

18. Alagille Syndrome Market Drivers

19. Alagille Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States